Pipeline Left Menu
R&D Pipeline
Product | Indication | Discovery | Preclinical | Phase 1 | Phase 2 | Phase 3 | Pre-registration | Approved / Market |
---|---|---|---|---|---|---|---|---|
Elepsia® XR (Levetiracetam ER) | Epilepsy |
|
||||||
Xelpros® (Latanoprost BAK Free) | Glaucoma |
|
||||||
Taclantis® (PICS) | Cancer |
|
||||||
SDN – 037 | Ocular Pain & Inflammation |
|
||||||
PDP - 716 | Glaucoma |
|
||||||
SCO – 088 | CML |
|
||||||
SCC - 138 | Parkinson’s Disease |
|
||||||
SCD – 044 | Autoimmune Disorders |
|
||||||
SCO - 120 | Breast Cancer |
|

Product | Elepsia® XR (Levetiracetam ER) |
Indication | Epilepsy |
Phase in US | Pre-registration |
Product | Xelpros® (Latanoprost BAK Free) |
Indication | Glaucoma |
Phase in US | Approved / Market |
Product | Taclantis® (PICS) |
Indication | Cancer |
Phase in US | Pre-registration |
Product | SDN – 037 |
Indication | Ocular Pain & Inflammation |
Phase in US | Pre-registration |
Product | PDP - 716 |
Indication | Glaucoma |
Phase in US | Phase 3 |
Product | SCO – 088 |
Indication | CML |
Phase in US | Phase 2 |
Product | SCC - 138 |
Indication | Parkinson’s Disease |
Phase in US | Phase 2 |
Product | SCD – 044 |
Indication | Autoimmune Disorders |
Phase in US | Phase 2 |
Product | SCO - 120 |
Indication | Breast Cancer |
Phase in US | Phase 1 |